Nasus Pharma (NSRX) Debt Ratio (2024)
Nasus Pharma (NSRX) reported Debt Ratio of 2.51 for Q4 2024.
Nasus Pharma (NSRX) Debt Ratio (2024) Analysis & Trends
Nasus Pharma has reported Debt Ratio for 1 years, with the latest figure at 2.51 in Q4 2024.
- For the quarter ending Q4 2024, Debt Ratio changed N/A year-over-year to 2.51; the trailing twelve-month figure through Dec 2024 stood at 2.51 (changed N/A YoY), and the FY2024 full-year result was 2.51, changed N/A from the prior year.
- Debt Ratio for Q4 2024 stood at 2.51.
- The five-year high for Debt Ratio was 2.51 in Q4 2024, with the low at 2.51 in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | -0.22 |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 0.37 |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 0.27 |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 0.47 |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 0.38 |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 0.62 |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 0.39 |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 0.31 |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 0.51 |
| 10 | Nasus Pharma | 24.83 Mn | 20.55 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 2.51 |